CD30 as a therapeutic target in adult haematological malignancies: Where are we now?

CD30 is a transmembrane protein from the tumour necrosis factor receptor superfamily. It is expressed on a small subset of activated T and B lymphocytes, and various lymphoid neoplasms. CD30 is a particularly interesting treatment target because its levels are high in tumours but low in healthy tissues. Several therapeutic strategies targeting CD30 have been developed, including monoclonal antibodies, conjugated antibodies (combination of brentuximab vedotin with chemotherapy or immunotherapy), bispecific antibodies and cell and gene therapies, such as anti-CD30 CAR-T cells in particular. We briefly review the biology of CD30 which makes it a good therapeutic target, and we describe all of the anti-CD30 therapies that have emerged to date.

Automated summary

CD30 is a transmembrane protein expressed on a subset of activated T and B lymphocytes as well as lymphoid neoplasms. It is a promising therapeutic target due to its high levels in tumors and low levels in healthy tissues. Various therapeutic strategies have been developed, including monoclonal antibodies, bispecific antibodies, and cell and gene therapies such as anti-CD30 CAR-T cells. This review provides an overview of the biology of CD30 and describes the current anti-CD30 therapies.